Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.33 |
| ▸ | OGFRL1 | Q5TC84 | 2/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
| ▸ | CCKBR | P32239 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 3/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3580109 | 0.80 | TYK2 (0.33) | L3MBTL1 | |
| SCHEMBL3577828 | 0.78 | MAPT (0.42) | KMT2A | |
| SCHEMBL3574051 | 0.76 | MTNR1A (0.39) | — | |
| SCHEMBL3581635 | 0.74 | ADAM17 (0.36) | OPRM1OPRD1OGFRL1OPRK1 | |
| SCHEMBL3581356 | 0.74 | ADAM17 (0.34) | OPRM1OPRD1OGFRL1OPRK1 | |
| SCHEMBL4043888 | 0.70 | JAK1 (0.34) | KMT2AL3MBTL1 | |
| SCHEMBL3583797 | 0.68 | JAK1 (0.35) | CCR1 | |
| SCHEMBL5264535 | 0.68 | KCNH2 (0.37) | KMT2A | |
| SCHEMBL5260906 | 0.66 | CDK8 (0.41) | — | |
| SCHEMBL5263242 | 0.66 | KCNH2 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100081650-A1 | Antimicrobial Compounds | AXTEN JEFFREY MICHAEL | 2010-04-01 | — | — | US | disclosed |
| US-7622481-B2 | Antibacterial compounds | GLAXO GROUP LIMITED (GB) | 2009-11-24 | — | — | US | disclosed |
| US-20060189604-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189604-A1 | Compounds | ELANE, PIGS, SDHA | CD274 2375/4885OPRM1 979/4885OPRD1 265/4885 |
| US-20100081650-A1 | Antimicrobial Compounds | ELANE, NISCH, PIGS | CD274 2908/4885OPRM1 1802/4885OPRD1 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.